Tempest Therapeutics Inc(TPST) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.48 | Insider Own | 39.64% | Shs Outstand | 16.0M | Perf Week | 2.22% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 68.42% | Insider Trans | 3.58% | Shs Float | 10.2M | Perf Month | -33.37% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.32 | Inst Own | 6.31% | Short Float | 3.07% | Perf Quarter | -37.49% |
| Income | -0.04B | P/S | - | EPS this Y | 54.98% | Inst Trans | 17.08% | Short Ratio | 0.12 | Perf Half Y | -68.97% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -237.25% | Short Interest | 0.31M | Perf YTD | -81.19% |
| Book/sh | -0.07 | P/C | 11.7 | EPS past 3/5Y | 46% 76.03% | ROE | -931.14% | 52W High | -95.14% ($11.12) | Perf Year | -95.04% |
| Cash/sh | 0.05 | P/FCF | - | Sales past 3/5Y | - | ROIC | -780.86% | 52W Low | 7.87% ($0.50) | Perf 3Y | -99.02% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 69.34% | Gross Margin | - | Volatility(W/M) | 5.59% 7.07% | Perf 5Y | -99.66% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.06 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 0.38 | EPS Q/Q | 83.35% | Profit Margin | - | RSI (14) | 32.81 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.38 | Sales Q/Q | - | SMA20 | -17.8% ($0.66) | Beta | -1.6 | Target Price | $7 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | -35.71% ($0.84) | Rel Volume | 0.04 | Prev Close | $0.51 |
| Employees | 4 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -64.61% ($1.53) | Avg Volume(3M) | 2.54M | Price | $0.54 |
| IPO | 2012/11/12 | Option/Short | No/Yes | Trades | 281 | Volume | 103,701 | Change | 5.72% |
Tempest Therapeutics is a clinical-stage biotech headquartered in Brisbane, California, USA, developing targeted and immune therapies that simultaneously address tumor cells and the immune microenvironment. Its lead candidate is amezalpat, an oral PPARα antagonist aimed at first-line treatment of hepatocellular carcinoma (HCC), and the company has recently added a dual CAR-T program to its portfolio.
Over the past 1 year, on the lower side
95% below its 1-year high.
Traded less than usual. That is 4% of its average volume.
TPST has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +55.0% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.7%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 6.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #510 of 594 in the industry
Based on market cap of $9M.
ACTU#508 Actuate Therapeutics Inc $9M PER - 
MBRX#509 Moleculin Biotech Inc $9M PER - TPST#510 Tempest Therapeutics Inc $9M PER - 
PTN#511 Palatin Technologies Inc $9M PER - 
ENSC#512 Ensysce Biosciences Inc $9M PER - 
FAQ
What kind of company is TPST?
TPST belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TPST?
The market cap of TPST is approximately $9M, ranking 5,464 within its sector.
What is the 52-week high and low for TPST?
TPST has recorded a 52-week high of $11.12 and a low of $0.50.
